601567:SSENingbo Sanxing Medical Electric Co., Ltd. Class A Analysis
Data as of 2026-03-17 - not real-time
CN¥29.44
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Ningbo Sanxing Medical Electric is trading at CNY 29.44, comfortably above its 20‑day (CNY 27.68), 50‑day (CNY 25.75) and 200‑day (CNY 23.95) moving averages, indicating a strong bullish momentum reinforced by a bullish MACD crossover and an RSI of 58. Valuation appears reasonable with a trailing P/E of 21 versus an industry average of 29, and a forward P/E of 15.5, while the stock offers an attractive dividend yield of 4.67% and a payout ratio of 64%. However, the company faces a 9.6% revenue decline and a high debt load (debt‑to‑equity ~28%), with negative free cash flow despite solid operating cash generation. The combination of bullish technicals, solid dividend income, and a modest beta of 0.58 suggests upside potential, but the earnings slowdown and leverage pose downside risks.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Price above key moving averages
- Bullish MACD and supportive RSI
- High dividend yield
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Valuation advantage vs industry peers
- Revenue contraction risk
- Elevated debt level
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Sustainable dividend income
- Potential for earnings turnaround
- Ongoing leverage and cash flow concerns
Key Metrics & Analysis
Financial Health
Revenue Growth-9.60%
Profit Margin12.93%
P/E Ratio21.2
ROE15.95%
ROA5.34%
Debt/Equity28.26
P/B Ratio3.3
Op. Cash FlowCN¥1.3B
Free Cash FlowCN¥-233902480
Industry P/E29.4
Technical Analysis
TrendBullish
RSI58.2
SupportCN¥23.27
ResistanceCN¥33.66
MA 20CN¥27.68
MA 50CN¥25.75
MA 200CN¥23.95
MACDBullish
VolumeIncreasing
Fear & Greed Index81.48
Valuation
Fair ValueCN¥8.25
GradeFair
TypeBlend
Dividend Yield4.67%
Risk Assessment
Beta0.58
Volatility55.52%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.